Study of RMC-5127 in Patients With Advanced KRAS G12V-Mutant Solid Tumors

This study is testing a new targeted drug called RMC-5127 for people with advanced cancers that have a specific mutation called KRAS G12V. KRAS mutations are found in many difficult-to-treat cancers, and this drug is designed to directly block the mutated KRAS protein. **You may be eligible if...** - You are 18 or older - Your cancer has a confirmed KRAS G12V mutation and has spread or cannot be surgically removed - Your cancer progressed on or you could not tolerate previous standard treatments - You are in good physical condition (ECOG 0 or 1) - You can swallow tablets and have adequate organ function **You may NOT be eligible if...** - Your cancer started in the brain (primary CNS tumor) - You have previously received a KRAS G12V inhibitor or direct RAS-targeting therapy - You had major surgery in the past 28 days - You cannot comply with study visits or procedures Talk to your doctor to see if this trial is right for you.